 This study investigates the effects of a PACAP receptor antagonist on central sensitization in a chronic migraine model. It found that the antagonist reduced the number of CFAS positive cells in the trigeminal nucleus cordylus, suggesting that it can reduce the pain sensitivity associated with chronic migraines. Additionally, the antagonist also decreased the levels of FAS-related ERK-1 or 2 and CREB, as well as BDNF, indicating that it can prevent the activation of the ERK, the CREB, a BDNF signaling pathway. These findings suggest that PACAP receptor antagonists have the potential to be used as a novel treatment option for chronic migraine patients. This article was authored by Lily Jong, Yen Jieju, Liu Yang, and others.